BEVERLY HILLS, California — February 6, 2026 — Leads & Copy — Nordicus Partners Corporation (OTCQB: NORD) is providing a corporate update, highlighting developments in its subsidiaries and the status of its Nasdaq uplisting application.
Nordicus, a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, notes that Orocidin’s first pilot efficacy study in patients is anticipated to start in Q3 2026 at the University of Copenhagen in Denmark. This study will begin upon completion of the GMP (Good Manufacturing Practice) for the clinical use of the product. Additionally, a pivotal 8-week toxicology study is about to be initiated and is expected to be completed by April 2026.
Bio-Convert expects the final GMP (Good Manufacturing Practice) product to be completed by August 2026. Patient testing of Bio-Convert’s product, QR-02, is anticipated to begin in Q3 2026 in Gothenburg, Sweden.
NoviThera’s development is progressing according to plan. A mouse study is currently running in which the mice receive different doses of the pathogenic polypeptide in increasing concentrations comparing control (inactive saline). The objective is to determine whether increasing levels of the polypeptide drives the development of psoriasis. Once the study is finalized in approximately one month, Nordicus will report the results and the next milestones for NoviThera.
Nordicus applied to uplist its common shares from the OTCQB Market to the Nasdaq Capital Market and the process is still ongoing.
The Company continues to scout the Nordic region for additional accelerator clients and possible new high growth acquisitions in the life sciences space.
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. In 2024, Nordicus acquired 100% of Orocidin A/S and 100% of Bio-Convert A/S.
Source: Nordicus Partners Corporation
